Table 4.
Clinicopathologic characteristics between Groups A and B
| Group A (n=164) | Group B (n=229) | P value | ||
|---|---|---|---|---|
| Age | 59.9±12.1 | 56.5±13.0 | 0.009 | |
| Sex | Male:Female | 2.5:1 (117/47) | 2.6:1 (166/63) | 0.820 |
| Differentiation | Differentiated | 90 (54.9%) | 73 (31.9%) | <0.001 |
| Undifferentiated | 74 (45.1%) | 148 (64.6%) | ||
| Unknown | 0 | 8 (3.5%) | ||
| Lauren | Intestinal | 91 (55.5%) | 74 (32.3%) | <0.001 |
| Diffuse | 53 (32.3%) | 107 (46.7%) | ||
| Mixed | 20 (12.2%) | 45 (19.7%) | ||
| Unknown | 0 | 3 (1.3%) | ||
| Lymphatic invasion | Invasion (+) | 90 (54.9%) | 152 (66.4%) | 0.027 |
| Invasion (−) | 74 (45.1%) | 77 (33.6%) | ||
| Venous invasion | Invasion (+) | 28 (17.1%) | 44 (19.2%) | 0.692 |
| Invasion (−) | 136 (82.9%) | 185 (80.8%) | ||
| Perineural invasion | Invasion (+) | 65 (39.6%) | 13 (58.1%) | <0.001 |
| Invasion (−) | 99 (60.4%) | 96 (41.9%) | ||
| Size (cm) | 5.1±2.4 | 6.1±3.5 | 0.001 | |
| Metastatic LN | 4.5±8.2 | 6.8±9.2 | 0.008 | |
| Retrieved LN | 31.1±13.0 | 31.7±12.9 | 0.635 | |
| Radicality | R0 | 153 (93.3%) | 196 (85.6%) | 0.022 |
| R1/R2 | 11 (6.7%) | 33 (14.4%) | ||
| T stage | T1 | 54 (32.9%) | 43 (18.8%) | 0.008 |
| T2 | 25 (15.2%) | 39 (17.0%) | ||
| T3 | 56 (34.1%) | 85 (37.1%) | ||
| T4 | 29 (17.7%) | 62 (27.1%) | ||
| N stage | N0 | 76 (46.3%) | 79 (34.5%) | 0.003 |
| N1 | 26 (15.9%) | 32 (14.0%) | ||
| N2 | 28 (17.1%) | 30 (13.1%) | ||
| N3 | 34 (20.7%) | 88 (38.4%) | ||
| M stage | M0 | 151 (92.1%) | 192 (83.8%) | 0.016 |
| M1 | 13 (7.9%) | 37 (16.2%) | ||
| TNM stage | Stage I | 64 (39.0%) | 60 (26.2%) | 0.009 |
| Stage II | 40 (24.4%) | 51 (22.3%) | ||
| Stage III | 47 (28.7%) | 81 (35.4%) | ||
| Stage IV | 13 (7.9%) | 37 (16.2%) |
Group A indicates the positive expression group in which ≥ 3 proteins among membranous type MUC13m, CDH17, LGALS4 and REG4 were expressed. Group B indicates the expression loss group in which ≤ 2 proteins among membranous type MUC13, CDH17, LGALS4 and REG4 were expressed.